UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022613
Receipt number R000026051
Scientific Title Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy
Date of disclosure of the study information 2016/07/01
Last modified on 2020/12/08 13:58:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy

Acronym

Efficacy of mirabegron in patient treathed with brachytherapy

Scientific Title

Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy

Scientific Title:Acronym

Efficacy of mirabegron in patient treathed with brachytherapy

Region

Japan


Condition

Condition

prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy for voiding disorder in patients who underwent low-dose-rate brachytherapy

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the change from baseline to three months later after brachytherapy in mean volume voided per micturition

Key secondary outcomes

the change from baseline to three months later after brachytherapy in IPSS,OABSS, and EPIC
the change from baseline to three months later after brachytherapy in maximum urinary flow rate, residual urine volume, and mean number of micturitions per 24 hours.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Treatments were administered once daily (tamsrosin 0.2mg) during 12 months after low-dose-rate brachytherapy

Interventions/Control_2

Treatments were administered once daily (mirabegron 50mg) during 3 months after low-dose-rate brachytherapy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male

Key inclusion criteria

patients who underwent low-dose-rate brachytherapy

Key exclusion criteria

considered unsuitable for the trial by doctors
residual urine volume greater than 100 ml
Qmax less than 5 ml per second
contraindicated to medication with mirabegron
history of urinary retention
performance of clean intermittent catheterization

Target sample size

240


Research contact person

Name of lead principal investigator

1st name Yasushi
Middle name
Last name Nakai

Organization

Nara Medical University

Division name

Department of Urology

Zip code

6348522

Address

840 Shijo-cho, Kashihara-shi, Nara, Japan

TEL

0744-22-3051

Email

nakaiyasushi@naramed-u.ac.jp


Public contact

Name of contact person

1st name Yasushi
Middle name
Last name Nakai

Organization

Nara Medical University

Division name

Department of Urology

Zip code

6348522

Address

840 Shijo-cho, Kashihara-shi, Nara, Japan

TEL

0744-22-3051

Homepage URL


Email

nakaiyasushi@naramed-u.ac.jp


Sponsor or person

Institute

Nara Medical University
Department of Urology

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nara Medical University

Address

840 Shijyocho Kashihara Nara

Tel

0744-22-3051

Email

nakaiyasushi@naramed-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

218

Results


Results date posted


Results Delayed

Delay expected

Results Delay Reason

The results will be reported at ASTRO in 25th-28th October.

Date of the first journal publication of results

2020 Year 10 Month 25 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD

None

IPD sharing Plan description

None


Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 06 Month 20 Day

Date of IRB

2016 Year 08 Month 17 Day

Anticipated trial start date

2016 Year 07 Month 01 Day

Last follow-up date

2018 Year 12 Month 03 Day

Date of closure to data entry

2018 Year 12 Month 26 Day

Date trial data considered complete

2018 Year 12 Month 26 Day

Date analysis concluded

2019 Year 07 Month 14 Day


Other

Other related information



Management information

Registered date

2016 Year 06 Month 05 Day

Last modified on

2020 Year 12 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026051


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name